Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics (Premium)
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Enters License Agreement with Janssen to Develop and Commercialize ASP015K


Monday, 1 Oct 2012 07:00pm EDT 

Astellas Pharma Inc announced the execution of a license agreement with Janssen Biotech, Inc., under which Janssen Biotech, Inc.has an exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan. In return for the exclusive license to develop and commercialize ASP015K in the Territory, Astellas is entitled to receive an up-front payment of $65 million from Janssen. Astellas is also eligible to receive contingent payments upon the achievement of certain development, regulatory and commercial milestones, which could total up to $880 million. Astellas is further entitled to receive double-digit royalty payments on net sales of ASP015K in the Territory from Janssen. After completion of the Phase IIb studies in the Territory, Janssen is responsible for all future costs associated with the development and commercialization of ASP015K for rheumatoid arthritis and other autoimmune indications in the Territory. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K is a oral Janus Kinase (JAK) inhibitor which Astellas is developing for rheumatoid arthritis. 

Company Quote

1515.5
0.5 +0.03%
22 Aug 2014